Current role of cytoreductive nephrectomy in metastatic renal cell carcinoma.
Journal
Turkish journal of urology
ISSN: 2149-3235
Titre abrégé: Turk J Urol
Pays: Turkey
ID NLM: 101643563
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
entrez:
5
8
2022
pubmed:
1
2
2021
medline:
1
2
2021
Statut:
ppublish
Résumé
Historically, immediate cytoreductive nephrectomy (CN) was considered the standard of care in patients with metastatic renal cell carcinoma (mRCC) who were fit enough to undergo surgery. Recently, 2 randomized controlled trials, SURTIME and CARMENA, have questioned the role of immediate CN and initiated an ongoing debate on the proper indications and timing of CN. Although some patients still benefit from immediate CN, other patients require immediate systemic treatment, and some of them might benefit from deferred CN in the absence of disease progression. This study provides an overview of the history of CN, an in-depth analysis of SURTIME and CARMENA, and highlights the current indications for performing immediate or deferred CN.
Identifiants
pubmed: 35929921
doi: 10.5152/tud.2021.21006
pmc: PMC8057358
doi:
Types de publication
Journal Article
Langues
eng
Pagination
S79-S84Références
Cancer. 2010 Jul 15;116(14):3378-88
pubmed: 20564061
J Urol. 2018 Sep;200(3):528-534
pubmed: 29574109
J Urol. 2004 Mar;171(3):1071-6
pubmed: 14767273
Cochrane Database Syst Rev. 2008 Apr 16;(2):CD006017
pubmed: 18425931
CA Cancer J Clin. 2020 Jan;70(1):7-30
pubmed: 31912902
Eur Urol Oncol. 2020 Aug;3(4):523-529
pubmed: 32414697
Eur Urol. 2020 Oct;78(4):615-623
pubmed: 32362493
J Clin Oncol. 2014 Sep 1;32(25):2765-72
pubmed: 25049330
JAMA Oncol. 2019 Feb 1;5(2):164-170
pubmed: 30543350
Eur Urol. 2019 May;75(5):799-810
pubmed: 30803729
Urology. 2015 Feb;85(2):442-50
pubmed: 25623717
J Urol. 1978 Aug;120(2):148-52
pubmed: 78992
N Engl J Med. 2001 Dec 6;345(23):1655-9
pubmed: 11759643
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Scand J Urol. 2020 Dec;54(6):493-499
pubmed: 32924729
Eur Urol. 2014 Oct;66(4):704-10
pubmed: 24931622
J Urol. 1993 Aug;150(2 Pt 1):463-6
pubmed: 8326579
N Engl J Med. 2018 Aug 02;379(5):417-427
pubmed: 29860937
Eur Urol. 2019 Jan;75(1):111-128
pubmed: 30467042
BJU Int. 2020 Dec;126(6):745-753
pubmed: 32623821
J Clin Oncol. 1999 Aug;17(8):2530-40
pubmed: 10561319
Urol Oncol. 2021 Jan;39(1):77.e17-77.e25
pubmed: 32863124
J Clin Oncol. 2009 Dec 1;27(34):5794-9
pubmed: 19826129
Eur Urol. 2019 Feb;75(2):352-353
pubmed: 30420256
Scand J Urol. 2014 Jun;48(3):231-8
pubmed: 24666102
N Engl J Med. 2007 Jan 11;356(2):115-24
pubmed: 17215529
Cell. 2018 Apr 19;173(3):581-594.e12
pubmed: 29656895
Lancet. 2001 Sep 22;358(9286):966-70
pubmed: 11583750
Ther Adv Med Oncol. 2019 Sep 27;11:1758835919879026
pubmed: 31632471
Eur Urol. 2021 Jun;79(6):783-792
pubmed: 33172722